Biota Pharmaceuticals Announces Appointment of New Executive

Biota Pharmaceuticals Announces Appointment of New Executive Officers 
ROCKVILLE, MD -- (Marketwire) -- 11/14/12 --  Biota Pharmaceuticals,
Inc. (NASDAQ: BOTA) today announced the appointment of Russell H.
Plumb as its Chief Executive Officer and Joseph M. Patti, M.S.P.H.,
Ph.D. as Executive Vice President, Corporate Development & Strategy.
Mr. Plumb will also join the Board of Directors.  
"Biota's move to the United States marks the beginning of a
transformative period for the company. With two drugs on the market
and a robust pipeline anchored by laninamivir, Biota represents a
truly unique opportunity and I'm excited to play a role in maximizing
the Company's potential," commented Russell H. Plumb, Biota
Pharmaceuticals Chief Executive Officer. 
Mr. Plumb previously served as President, Chief Executive Officer and
Chief Financial Officer of Inhibitex, Inc., a U.S. publicly-traded
clinical-stage drug development company, from December 2006 through
February 2012, when it was acquired by Bristol-Myers Squibb for
approximately $2.5 billion. Prior to its acquisition, Inhibitex had
focused its resources in recent years on developing antiviral, small
molecules, including compounds to treat hepatitis C virus (HCV)
infection. From 2000 to December 2006, Mr. Plumb was the Chief
Financial Officer of Inhibitex, during which time he oversaw numerous
financing transactions, including the company's initial public
offering in 2004.  
Dr. Patti was a co-founder of Inhibitex, and served as Chief
Scientific Officer and Senior Vice President of Research and
Development of Inhibitex from 2007 through February 2012. Prior to
that, he served as the Vice President, Preclinical Development and
Chief Scientific Officer of Inhibitex from 1998 to 2007 and Vice
President of Research and Development from 2005 to 2007. 
"Russ and Joe are talented and proven executives who bring a
successful track record of leading and operating drug development
companies," said Jim Fox, Chairman of the Board of Directors of
Biota. "I believe that the strong commercial skills exhibited by Russ
and Joe will augment the excellent science of Biota and create a
unique value proposition for our shareholders."  
Peter Cook, who resigned as the Chief Executive Officer of Biota
Holdings upon the completion of the previously announced merger
transaction between Biota Holdings Limited and Nabi
Biopharmaceuticals that created Biota Pharmaceuticals, Inc., serves
as a director of the company. 
About Biota
 Biota is a leading anti-infective drug development
company, based in Rockville, Maryland with key expertise in
respiratory diseases, particularly influenza.  
Biota developed its first-in-class neuraminidase inhibitor,
zanamivir, subsequently marketed by GlaxoSmithKline as Relenza(TM).
Biota research breakthroughs include a series of candidate drugs
aimed at treatment of respiratory syncytial virus (RSV) disease and
hepatitis C (HCV) virus infections. Biota also has an advanced
program for the treatment of human rhinovirus (HRV) infection, with a
successfully completed Phase IIb study in asthmatic subjects. 
In addition, Biota and Daiichi Sankyo co-own a range of second
generation influenza antivirals, of which the lead product,
laninamivir, is approved and marketed as lnavir(R) in Japan. Biota
also holds a contract from the U.S. Office of Biomedical Advanced
Research and Development Authority (BARDA) for the advanced
development of laninamivir in the USA.  
Relenza(TM) is a registered trademark of the GlaxoSmithKline group of
companies.
 Inavir(R) is registered to Daiichi Sankyo. 
Forward-Looking Statements  
Statements set forth above that are not strictly historical are
forward-looking statements. You can identify these forward-looking
statements because they involve our expectations, intentions,
beliefs, plans, projections, anticipations, or other
characterizations of future events or circumstances. These
forward-looking statements are not guarantees of future performance
and are subject to risks and uncertainties that may cause actual
results to differ materially from those in the forward-looking
statements as a result of any number of factors. These factors
include, but are not limited to, risks that are more fully discussed
in Biota's Annual Report on Form 10-K, as amended, for fiscal year
ended December 31, 2011, Quarterly Reports on Form 10-Q for the
quarters ended March 31 and June 30, 2012 and definitive proxy
statement for the stockholders special meeting filed with the SEC on
August 7, 2012, as supplemented by the supplement dated September 25,
2012, under the captions "Risk Factors" and "Cautionary Statement
Regarding Forward-Looking Statements" and elsewhere in such
documents. We do not undertake to update any of these forward-looking
statements or to announce the results of any revisions to these
forward-looking statements except as required by law. 
Further information 
Investor/Analyst Enquiries 
Biota Pharmaceuticals, Inc. 
Damian Lismore 
T: +61 3 9915 3721  
Media Enquiries
Blueprint Life Science Group
Hershel Berry
T: +1 415 375 3340 Ext. 102